GnRH Agonist Administration in the Luteal Phase of ICSI-ET Cycles

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00516490

Enrollment

570

Registered

2007-08-15

Start date

2006-09-30

Completion date

2007-07-31

Last updated

2007-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

GnRH agonist, IVF/ICSI outcome, luteal phase

Brief summary

A single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles was reported to increase pregnancy and birth rates. This study was done to evaluate the reproducibility of previous findings.

Detailed description

GnRH agonist administration in the luteal phase was reported to beneficially affect clinical outcome of ICSI-ET cycles. This randomized controlled trial evaluates the effect of a single dose GnRH agonist administered in the luteal phase on the outcome of ICSI - ET cycles stimulated with the long GnRH agonist protocol. Women undergoing embryo transfer following controlled ovarian hyperstimulation with a long GnRH agonist protocol were included. In addition to routine luteal phase support with progesterone women were randomized to receive a single dose of GnRH agonist or placebo on the sixth day after ICSI.Ongoing pregnancy rate was the primary outcome measure.

Interventions

DRUGtriptorelin acetate

Single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer

DRUGNa Cl %0.9

0.1 ml sterile saline subcutaneous injection on the 3rd day after embryo transfer

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* Women undergoing embryo transfer following controlled ovarian hyperstimulation with a long GnRH agonist protocol, oocyte pick-up and ICSI. * Embryo transfer performed on day 3.

Exclusion criteria

* Participation in another trial that was being conducted in our unit at the same time. * Preimplantation genetic screening cycles. * Day 5 embryo transfers.

Design outcomes

Primary

Measure	Time frame
Ongoing pregnancy rate beyond 20 weeks	—

Secondary

Measure	Time frame
Clinical pregnancy	—
Embryo implantation rate	—

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026